Cathay Biotech's (SHSE:688065) Anemic Earnings Might Be Worse Than You Think
Cathay Biotech's (SHSE:688065) Anemic Earnings Might Be Worse Than You Think
Cathay Biotech Inc.'s (SHSE:688065) recent weak earnings report didn't cause a big stock movement. However, we believe that investors should be aware of some underlying factors which may be of concern.
Cathay Biotech Inc.(SHSE:688065)最近的業績表現疲弱,並沒有引起股價大幅波動。然而,我們認爲投資者應該注意一些潛在的引起關注的因素。
The Impact Of Unusual Items On Profit
除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。
Importantly, our data indicates that Cathay Biotech's profit received a boost of CN¥80m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. Cathay Biotech had a rather significant contribution from unusual items relative to its profit to June 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.
重要的是,我們的數據顯示,Cathay Biotech的利潤在過去一年中因飛凡項目獲得了8000萬元人民幣的提振。雖然獲得更高的利潤總是令人愉快的,但飛凡項目帶來的大額貢獻有時會抑制我們的熱情。當我們分析了數千家上市公司的數據後,發現在某一年獲得飛凡項目的提振往往不會在下一年重複。這一點並不奇怪,鑑於其名稱。相對於其2024年6月的利潤,Cathay Biotech的飛凡項目貢獻相當顯著。其他條件相同的情況下,這可能導致合規利潤不是底層盈利力的一個良好指導。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Cathay Biotech.
注:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對Cathay Biotech資產負債表的分析。
Our Take On Cathay Biotech's Profit Performance
我們對Cathay Biotech的利潤表現看法
As we discussed above, we think the significant positive unusual item makes Cathay Biotech's earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Cathay Biotech's underlying earnings power is lower than its statutory profit. Sadly, its EPS was down over the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. To that end, you should learn about the 2 warning signs we've spotted with Cathay Biotech (including 1 which is a bit concerning).
正如我們上面所討論的,我們認爲顯著的正飛凡項目使得國泰生物的盈利成爲其潛在盈利能力的不良指標。因此,我們認爲國泰生物的潛在盈利能力很可能低於其法定利潤。不幸的是,其每股收益在過去十二個月內下滑。當然,在分析其盈利方面,我們只是剛剛觸及表層;人們還可以考慮邊際利潤、預測增長和投資回報率等其他因素。基於此,如果您希望對公司進行更多分析,了解涉及的風險是至關重要的。爲此,您應該了解我們在國泰生物發現的兩個預警信號(其中一個令人有些擔憂)。
This note has only looked at a single factor that sheds light on the nature of Cathay Biotech's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
這則說明僅僅是探討了揭示國泰生物利潤本質的單一因素。但還有許多其他方式可以影響您對一家公司的看法。一些人認爲高淨資產回報率是優質企業的良好跡象。儘管這可能需要您進行一些研究,您可能會發現,這些具有高淨資產回報率的公司集合或者這些持有內部股份比較顯著的股票清單會很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。